🔗 Share this article

As the United States proceeds with historic adjustments to its immunization recommendations, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by questioning Covid shots in the global health crisis and has zeroed in on alleged fatalities following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Schedule

Public health authorities planned to reveal radical changes to the childhood immunization program earlier this month, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with many the international standard with little proof for improved outcomes. The announcement has been delayed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to head the office this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for ending specific pediatric vaccine recommendations in the US in order to be more like Denmark's approach, a nation with nationalized medicine and a population roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

The appointee has no obvious background in medication creation, approval processes or management, which has been customary for former directors of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of the center would “be deeply familiar with legal statutes and the science of drug development”, commented Janet Woodcock. “Clearly, she lacks the kind of background that previous people who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock stated.

“Many people just focuses on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and each of these have to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial administrative component to the position, which oversees more than 5,000 personnel. “It’s a huge leadership role, if you perform it correctly,” she said.

Official Statement and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this assignment represents more teamwork among regulatory chiefs on vaccines, a representative responded that the “questions rely on flawed premises”.

“This background matches the functions of her position,” the spokesperson stated, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial one-day drug-approval program that allegedly worried her predecessors. “How are these therapies being chosen for this fast-track system? Who is making the decisions?” Howard questioned. “There is a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards laxer oversight of most medications, except for vaccines.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, some experts observe. She published a study using unverified public submissions to estimate the incidence of heart inflammation following Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership featured changing rules for recently developed shots and discontinuing “optional” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of preventing young men from receiving COVID-19 vaccines.

“She is an thorough true believer who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a very misleading, fraudulent manner,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined other dissenters, {like|